Jeet Mukherjee
Stock Analyst at BTIG
(4.77)
# 464
Out of 4,512 analysts
125
Total ratings
66.7%
Success rate
29.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeet Mukherjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Rated: Buy | $104 → $117 | $99.79 | +17.25% | 15 | Jul 1, 2026 | |
| NRIX Nurix Therapeutics | Rated: Buy | $32 | $22.98 | +39.25% | 12 | Jul 1, 2026 | |
| FTH Faeth Therapeutics | Maintained: Buy | $55 | $33.12 | +66.06% | 3 | Jul 1, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $138 → $134 | $112.08 | +19.56% | 13 | Jun 25, 2026 | |
| VSTM Verastem | Reiterated: Buy | $18 | $5.57 | +223.16% | 5 | Jun 24, 2026 | |
| AVBP ArriVent BioPharma | Maintained: Buy | $42 | $32.54 | +29.07% | 2 | May 29, 2026 | |
| AARD Aardvark Therapeutics | Downgraded: Hold | n/a | $6.26 | - | 9 | May 15, 2026 | |
| ARVN Arvinas | Reiterated: Buy | $16 → $18 | $8.27 | +117.65% | 12 | May 13, 2026 | |
| IPHA Innate Pharma | Maintained: Buy | $8 | $1.79 | +346.93% | 4 | May 13, 2026 | |
| AAPG Ascentage Pharma Group International | Maintained: Buy | $48 | $19.24 | +149.48% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.05 | +359.02% | 9 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $28.10 | -0.36% | 5 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 → $12 | $7.88 | +52.28% | 6 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $37.97 | +229.21% | 5 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $215 | $149.68 | +43.64% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $5.38 | +104.46% | 4 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $11.24 | n/a | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $91 | $25.67 | n/a | 2 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $0.93 | n/a | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $51.73 | n/a | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $100 | $15.78 | n/a | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $4.06 | n/a | 1 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $62 | $36.65 | n/a | 1 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.0057 | n/a | 1 | Apr 1, 2025 |
Monopar Therapeutics
Jul 1, 2026
Rated: Buy
Price Target: $104 → $117
Current: $99.79
Upside: +17.25%
Nurix Therapeutics
Jul 1, 2026
Rated: Buy
Price Target: $32
Current: $22.98
Upside: +39.25%
Faeth Therapeutics
Jul 1, 2026
Maintained: Buy
Price Target: $55
Current: $33.12
Upside: +66.06%
Kymera Therapeutics
Jun 25, 2026
Maintained: Buy
Price Target: $138 → $134
Current: $112.08
Upside: +19.56%
Verastem
Jun 24, 2026
Reiterated: Buy
Price Target: $18
Current: $5.57
Upside: +223.16%
ArriVent BioPharma
May 29, 2026
Maintained: Buy
Price Target: $42
Current: $32.54
Upside: +29.07%
Aardvark Therapeutics
May 15, 2026
Downgraded: Hold
Price Target: n/a
Current: $6.26
Upside: -
Arvinas
May 13, 2026
Reiterated: Buy
Price Target: $16 → $18
Current: $8.27
Upside: +117.65%
Innate Pharma
May 13, 2026
Maintained: Buy
Price Target: $8
Current: $1.79
Upside: +346.93%
Ascentage Pharma Group International
May 13, 2026
Maintained: Buy
Price Target: $48
Current: $19.24
Upside: +149.48%
May 12, 2026
Reiterated: Buy
Price Target: $14
Current: $3.05
Upside: +359.02%
May 11, 2026
Reiterated: Buy
Price Target: $28
Current: $28.10
Upside: -0.36%
May 8, 2026
Maintained: Buy
Price Target: $13 → $12
Current: $7.88
Upside: +52.28%
May 1, 2026
Reiterated: Buy
Price Target: $125
Current: $37.97
Upside: +229.21%
Apr 1, 2026
Reiterated: Buy
Price Target: $215
Current: $149.68
Upside: +43.64%
Mar 11, 2026
Maintained: Buy
Price Target: $11
Current: $5.38
Upside: +104.46%
May 23, 2025
Reiterated: Hold
Price Target: n/a
Current: $11.24
Upside: n/a
May 23, 2025
Maintained: Buy
Price Target: $91
Current: $25.67
Upside: n/a
May 21, 2025
Maintained: Buy
Price Target: $12
Current: $0.93
Upside: n/a
May 13, 2025
Initiated Coverage: Buy
Price Target: $42
Current: $51.73
Upside: n/a
May 9, 2025
Maintained: Buy
Price Target: $100
Current: $15.78
Upside: n/a
May 7, 2025
Maintained: Buy
Price Target: $10
Current: $4.06
Upside: n/a
Apr 14, 2025
Maintained: Buy
Price Target: $62
Current: $36.65
Upside: n/a
Apr 1, 2025
Reiterated: Hold
Price Target: n/a
Current: $0.0057
Upside: n/a